A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia

David W. Woessner*,1,†, Anna M. Eiring2,†, Benjamin J. Bruno3, Matthew S. Zabriskie2, Kimberly R. Reynolds2, Geoffrey D. Miller3, Thomas O’Hare2,4, Michael W. Deininger2,4,‡, and Carol S. Lim2,3,‡
1Department of Pharmacology and Toxicology, College of Pharmacy, The University of Utah, Salt Lake City, UT 84112, USA
2Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT 84112, USA
3Department of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The University of Utah, Salt Lake City, UT 84112, USA
4Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT 84112, USA

Abstract

Targeted therapy of chronic myeloid leukemia is currently based on small-molecule inhibitors that directly bind the tyrosine kinase domain of BCR-ABL1. This strategy has generally been successful, but is subject to drug resistance due to point mutations in the kinase domain. Kinase activity requires transactivation of BCR-ABL1 following an oligomerization event, which is mediated by the coiled-coil (CC) domain at the N-terminus of the protein. Here, we describe a rationally engineered mutant version of the CC domain, called CCmut3, which interferes with BCR-ABL1 oligomerization and promotes apoptosis in BCR-ABL1-expressing cells, regardless of kinase domain mutation status. CCmut3 exhibits strong pro-apoptotic and anti-proliferative activity in cell lines expressing native BCR-ABL1, single kinase domain mutant BCR-ABL1 (E255V and T315I) or compound mutant BCR-ABL1 (E255V/T315I). Moreover, CCmut3 inhibits colony formation by primary CML CD34+ cells ex vivo, including a sample expressing the T315I mutant.
These data suggest that targeting BCR-ABL1 with CC mutants may provide a novel alternative strategy for treating patients with resistance to current targeted therapies.

**Keywords**
- CML; BCR-ABL1; Coiled-coil domain; TKI-resistant; CCmut3; Kinase mutation; Compound mutant

**Introduction**

Chronic myeloid leukemia (CML) is caused by BCR-ABL1, the product of a reciprocal translocation t(9;22)(q34;q11)\(^1\),\(^2\), resulting in a shortened chromosome 22, also known as the Philadelphia chromosome. BCR-ABL1 is a constitutively active tyrosine kinase and the target of small-molecule inhibitors, including the first clinical tyrosine kinase inhibitor (TKI), imatinib\(^3\)–\(^5\). Overall, imatinib has demonstrated considerable efficacy in CML, with high rates of complete hematologic and cytogenetic responses that have translated into improved progression-free and overall survival compared to non-TKI therapies such as interferon-\(\alpha\)\(^6\)–\(^11\). Although many imatinib responses are durable, some patients develop kinase domain mutations that confer resistance to imatinib and are associated with clinical relapse\(^12\). These mutations impair imatinib binding and restore BCR-ABL1 kinase activity\(^13\). To overcome this type of resistance, the second-generation TKIs, dasatinib, nilotinib, and bosutinib, and most recently the third-generation TKI, ponatinib, were developed\(^14\). Second generation TKIs are active against most imatinib-resistant BCR-ABL1 mutants, with the exception of T315I (BCR-ABL1\(^{T315I}\))\(^15\). In contrast to imatinib and second generation TKIs, ponatinib is effective against the T315I mutant, representing a major therapeutic breakthrough\(^16\),\(^17\). Thus far, no single mutation (except for T315M, observed emanating from an initial T315I mutant in one patient following ponatinib therapy) has been shown to confer resistance to ponatinib\(^18\); however, multiple mutations in the same BCR-ABL1 molecule, referred to as compound mutations, can confer resistance to ponatinib both in vitro\(^19\) and in patients with clinical resistance to approved TKIs\(^17\),\(^18\).

Rational therapy of CML has generally focused on targeting the BCR-ABL1 catalytic site, but kinase domain mutations that impair or block drug binding limit the scope of this approach\(^20\). The N-terminal coiled-coil (CC) dimerization domain of BCR-ABL1 has been shown to be critically important for BCR-ABL1 kinase activity and could thus represent an alternative therapeutic target\(^21\),\(^22\). A peptidomimetic to block dimerization has been explored by several groups. Ruthardt et al. reported that introduction of a peptidomimetic of helix \(\alpha\)2 of the CC dimerization region reduced BCR-ABL1 phosphorylation and inhibited the proliferation of cells expressing native and mutant BCR-ABL1\(^23\). However, the isolated native helix 2 alone was inactive in cells expressing the T315I mutant\(^23\),\(^24\).

We recently described two iterations of a mutant CC (called CC\(^{mut2}\) and CC\(^{mut3}\)) with preferential specificity toward hetero-oligomerization with the CC region of BCR-ABL1 over homo-oligomerization with itself\(^25\),\(^26\). This construct is similar to the Ruthardt helix \(\alpha\)2 mimic, but contains the full-length CC domain. Additionally, CC\(^{mut3}\) incorporates engineered mutations to enhance binding specificity within helix \(\alpha\)2 and demonstrates
inhibitory activity against cells expressing native BCR-ABL1 or the T315I mutant. Here, we have studied the effects of C{sup mut3} against kinase domain mutant variants of BCR-ABL1 in both cell lines and primary CD34{sup +} cells from newly diagnosed and TKI-resistant CML patients.

**Materials and Methods**

**DNA Constructs**

pmCherry-EV (empty vector) and pmCherry-C{sup mut3} have been described. The lentiviral control vector pCDH-EF1-copGFP-EV was adapted from pCDH-CMV-MCS-EF1-copGFP (System Biosciences (SBI), Mountain View, CA, USA). The CMV promoter and multiple cloning sites were excised using SpeI and XbaI with compatible cohesive ends. The CMV fragment was removed using gel purification and the resulting DNA was ligated to form the final construct.

To make pCDH-EF1-copGFP-CC{sup mut3}, sections of the construct were amplified separately by PCR and joined using overlap extension PCR. First, EF1-copGFP was amplified from the SBI parent plasmid with a 5'-SpeI and 3'-BamHI site using the following primers: 5'-CAACTAGTAAGGATCTGCGATCGCTCC-3' and 5'-CCATCTGGAGTCCGGAGCGAGATCCGGTGGAGC-3'. CC{sup mut3} was amplified from pEGFP-CC{sup mut3} as described using primers containing a 5'-BamHI site, a terminal TAG stop signal and a sequence complementary to the polyA signal on the 3' overhang: 5'-CTCAGATGGATCTTTATGGTGGACCCGGTGAGGCTCC-3' and 5'-GTTATCTAGATCTACCGGTCATAGCTCTTTTCTTCCC-3'. Finally, the polyA signal from pEGFP-C1 (Clontech Laboratories, Mountain View, CA, USA) was amplified to include a 5' complementary sequence to CC{sup mut3}, and a 3'-SalI restriction site: 5'-GACCCGGTAGATCTTATACTGATCATATAATC-3' and 5'-GCTTACATGCGGCCGCGTCGACTGTGGGAGGTTTTTTAAAGC-3'. PCR products were combined in two steps, first by combining the CC{sup mut3}-polyA and then by adding EF1-copGFP by overlap extension PCR. The PCR product was digested with SpeI and SalI and ligated to the SpeI and SalI-digested pCDH-CMV-MCS-EF1-copGFP vector (SBI). The lentiviral packaging plasmid psPAX2 was purchased from Cellecta, Inc. (Mountain View, CA, USA), and the viral envelope plasmid pVSV-G was purchased from Clontech Laboratories.

**Cell Lines and Patient Samples**

Stable Ba/F3 cells transduced with native (p210) BCR-ABL1, the kinase domain mutants BCR-ABL{T315I}, BCR-ABL{E255V}, or the compound mutant BCR-ABL{E255V/T315I} were cultured as described. Briefly, cells were cultured in RPMI 1640 with 10% FBS, 100 U/ml penicillin-streptomycin, 2 mM L-glutamine, and 0.1% gentamycin (complete RPMI medium). Additionally, 0.1% MycoZap™ (Lonza Bio, Basel, Switzerland) was added to prevent mycoplasma contamination. The non-transduced parental Ba/F3 cell line was grown in RPMI 1640 supplemented with 20% WEHI-3B conditioned medium as a source of murine IL-3. To introduce CC{sup mut3} or empty vector (EV), Ba/F3 cells were transfected with plasmid DNA using the Amaxa nucleofection system (Lonza, Basel, Switzerland) using program X-001 following the manufacturer’s instructions. Cells were sorted on a BD
FACSAria cytometer (BD Biosciences, San Jose, CA, USA) for double-positive cells expressing mCherry and GFP prior to use in experiments.

Mononuclear cells (MNCs) from peripheral blood of patients with newly diagnosed or TKI-resistant CML were separated by Ficoll (Nycomed, Oslo, Norway), and the CD34⁺ fraction was isolated using an autoMACS Pro Separator (Miltenyi Biotech, San Diego, CA, USA). Purity was determined to be >90% by flow cytometric analysis using a Guava 6HT flow cytometer (Millipore, Billerica, MA, USA). CD34⁺ progenitors were maintained at 1×10⁶ cells/mL in RPMI 1640 containing 20% FBS and 5 μL/mL StemSpan CC100 (Stem Cell Technologies, Vancouver, BC, Canada). Sanger sequencing was used to confirm BCR-ABL1 genotype. All patients gave their informed consent in accordance with the Declaration of Helsinki, and all studies with human specimens were approved by The University of Utah Institutional Review Board (IRB).

**Lentivirus Generation and Infection**

293FT cells (Life Technologies, Grand Island, NY, USA) were grown in DMEM with 10% FBS, 100 U/ml penicillin-streptomycin, 2 mM L-glutamine, 0.1 mM MEM-non-essential amino acids, and 1 mM sodium pyruvate (Life Technologies, Grand Island, NY, USA). Cells were passaged every 2–3 days in T75 flasks, and grown to 65% confluence in T175 flasks for transfection. For lentivirus generation, cells were co-transfected with the experimental construct pCDH-EF1-copGFP-EV or pCDH-EF1-copGFP-CC\textsuperscript{mut3}, pVSV-G and psPAX2 using the Profection® mammalian transfection system (Promega, Madison, WI, USA) according to manufacturer’s instructions. After 48 h, viral particles were complexed with polyethylene glycol overnight, pelleted, and concentrated to 100X in RPMI 1640. Lentiviral titers were determined as described\textsuperscript{32}. Primary CML cells were infected with lentivirus at a multiplicity of infection of 5 for each construct at 24 and again at 48 h following harvest (fresh cells) or thaw (frozen cells), respectively. Cells were sorted on a BD FACSAria cytometer for GFP-positive cells after 72 h prior to use in experiments.

**Cell Proliferation Assays**

Cell proliferation was assessed using a methanethiosulfonate-based viability assay (MTS assay) utilizing CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) according to manufacturer instructions. Briefly, 5×10³ viable cells were suspended in 100 μL complete RPMI medium per well in 96-well plates. Three independent samples were seeded in duplicate for each time point. Cell growth was assessed by MTS assay at 72 and 96 h. Readings at 490 nM were taken on a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, USA) after a 3 h incubation with MTS reagent. In patient sample experiments, cell proliferation was assessed by trypan blue exclusion. TKI treatments in cells were at the following concentrations for the listed patient-samples: imatinib (0 or 2.5 μM) for newly diagnosed (ND) CML samples; ponatinib (0, 10 nM) for CML samples harboring BCR-ABL1\textsuperscript{T315I}.

**Apoptosis Assays**

For analysis of apoptosis and necrotic cell death, cells were pelleted and resuspended in Annexin V-binding buffer (BD Biosciences), stained with anti-Annexin V-APC and 7-AAD

*Leukemia. Author manuscript; available in PMC 2016 February 01.*
(BD Biosciences or Life Technologies) and analyzed on a BD FACSCanto flow cytometer. In addition to the APC and 7-AAD channels, GFP- and mCherry-positive cells were also recorded.

**Colony Forming Assays**

Following selection of transfected cells by cell sorting, methylcellulose colony assays were performed by plating in 0.9% methylcellulose as described (Stem Cell Technologies; M3234 for Ba/F3 BCR-ABL1 native and mutant lines; M3434 for Ba/F3 parental cells; H4230 for CML patient samples)\(^{25,33}\). mCherry-positive Ba/F3 cells (1.1×10\(^3\) cells/plate) or GFP-positive primary CML CD34\(^+\) cells (1×10\(^3\) cells/plate) were seeded per dish in duplicate. In the case of CML patient samples, cells were plated in the presence of 1× StemSpan CC100 cytokine cocktail (StemCell Technologies). All cells were plated with or without the indicated TKI in three or more independent experiments. Plates were incubated at 37°C in a 5% CO\(_2\) humidified incubator. Colonies were counted 7–14 days later in an area of 50 μm\(^2\) per dish using an inverted microscope.

**Statistics**

Data are expressed as the means ± SEM from at least 3 independent experiments unless otherwise stated. Briefly, significant differences between groups in Ba/F3 cell proliferation experiments (n=3 in technical duplicates) were assessed in GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) using a two-way ANOVA with Bonferroni’s multiple comparisons test. A two-tailed student’s t-test was used to determine significant differences in Ba/F3 colony forming experiments (n=3 in technical duplicates) and flow cytometric analysis of apoptosis (n=3). One-way ANOVA and Tukey’s multiple comparison’s test was used for primary ND CML cell colony forming assays (n=4 in technical duplicates). A p-value of <0.05 was considered significant for all experiments.

**Results**

**CC\(^{\text{mut3}}\) expression inhibits proliferation, increases apoptosis, and impairs survival of cell lines expressing native BCR-ABL1**

We first investigated the antiproliferative effects of CC\(^{\text{mut3}}\) in Ba/F3 cells expressing native BCR-ABL1 and in unmanipulated parental Ba/F3 cells. Expression of the CC\(^{\text{mut3}}\) construct was confirmed by immunoblot analyses (Supplemental Figure 1a). Following transfection with EV or the CC\(^{\text{mut3}}\) construct, proliferation was measured by MTS assay at 72 and 96 h. No difference between EV or CC\(^{\text{mut3}}\) was observed in parental Ba/F3 cells at either time point (Figure 1a), whereas proliferation of Ba/F3 cells expressing native BCR-ABL1 was reduced by >2-fold at 96 h (Figure 1b). To determine whether CC\(^{\text{mut3}}\) promoted apoptosis, we measured Annexin V and 7-AAD at 72 h in BCR-ABL1 cells with CC\(^{\text{mut3}}\) or EV. While there was no effect on the parental cell line (Figure 1c), BCR-ABL1-expressing cells showed an approximately 3-fold increase of apoptotic cells when transfected with CC\(^{\text{mut3}}\) compared to the EV control (Figure 1d). Finally, we tested the effect of CC\(^{\text{mut3}}\) on survival of parental and native BCR-ABL1-expressing Ba/F3 cells by colony formation assays. Similar to its effects on cell proliferation, CC\(^{\text{mut3}}\) nearly eliminated colony forming ability compared to the EV in BCR-ABL1-expressing cells, with no effect on parental Ba/F3
controls (Figures 1e and 1f). These data confirm that our CC\textsuperscript{mut3} mimetic is effective in the Ba/F3 cell line system expressing the BCR-ABL1 oncoprotein.

**CC\textsuperscript{mut3} inhibits proliferation, increases apoptosis, and impairs survival of cell lines harboring BCR-ABL1 single kinase domain mutants**

Next we tested the effects of CC\textsuperscript{mut3} on Ba/F3 cells expressing BCR-ABL1 mutants associated with clinical imatinib failure\(^\text{34, 35}\). Ba/F3 cells engineered to express either BCR-ABL\textsubscript{E255V} or BCR-ABL\textsubscript{T315I} were transfected with EV or CC\textsuperscript{mut3} constructs. Expression of the CC\textsuperscript{mut3} construct was again confirmed by immunoblot analyses (Supplemental Figure 1a). At 96 h, single mutants showed an approximately 3-fold reduction of proliferation when transfected with CC\textsuperscript{mut3} compared to EV, whereas a lesser, yet significant difference was noted at the 72 h time point (Figures 2a and 2b). Both BCR-ABL\textsubscript{E255V} and BCR-ABL\textsubscript{T315I} cells demonstrated a 6–8-fold increase in apoptosis (AnnexinV\(^+/\)7AAD\(^-\)) after transfection with CC\textsuperscript{mut3} when compared to the EV after 72 h (Figures 2c and 2d). Lastly, we assessed the effects of CC\textsuperscript{mut3} on survival of Ba/F3 cells harboring single BCR-ABL1 mutants by plating in colony formation assays. CC\textsuperscript{mut3} expression produced a >10-fold reduction of colony forming ability in both BCR-ABL\textsubscript{E255V} (Figure 2e) and BCR-ABL\textsubscript{T315I} cells (Figure 2f) compared to the EV controls. Altogether, these data demonstrate that CC\textsuperscript{mut3} not only inhibits growth of cells harboring non-mutated BCR-ABL1, but also inhibits growth of cells harboring clinically relevant BCR-ABL1 kinase domain single mutants.

**CC\textsuperscript{mut3} exerts anti-apoptotic and survival inhibitory effects on cell lines harboring a ponatinib-resistant BCR-ABL1 compound mutant**

Compound mutations are arising as a clinical problem in patients undergoing sequential TKI therapy\(^\text{18, 36, 37}\). To determine whether CC\textsuperscript{mut3} also has growth inhibitory effects on cells harboring BCR-ABL1 compound mutants, we introduced CC\textsuperscript{mut3} or the EV into Ba/F3 cells expressing the highly TKI-resistant BCR-ABL1\textsubscript{E255V/T315I} compound mutant. Expression of the CC\textsuperscript{mut3} construct was again confirmed by immunoblot analyses (Supplemental Figure 1a). Importantly, CC\textsuperscript{mut3} significantly reduced proliferation of compound mutant cells at 96 h (Figure 3a), although the effects were far less pronounced than that observed in the single kinase domain mutant cells (Figures 2a and 2b). However, CC\textsuperscript{mut3} effectively induced apoptosis of Ba/F3 cells expressing BCR-ABL1\textsubscript{E255V/T315I} (Figure 3b) to a similar degree seen in single kinase mutants 72 h following transfection (Figures 2c and 2d). Importantly, CC\textsuperscript{mut3} expression in cells harboring the BCR-ABL1\textsubscript{E255V/T315I} compound mutant reduced colony forming ability by approximately 50% compared to EV controls (Figure 3c). Thus, these data extend the effects of CC\textsuperscript{mut3} to include not only native and single kinase domain mutant BCR-ABL1, but also cells harboring highly TKI-resistant compound mutant clones.

**CD34\(^+\) cells from CML patients harboring native or T315I mutant BCR-ABL1 are sensitive to CC\textsuperscript{mut3}**

Lentivirus expressing CC\textsuperscript{mut3} or EV (Supplemental Figure 1b–c) was used to infect CD34\(^+\) cells isolated from blood or bone marrow of ND CML patients, and cultured in complete RPMI 1640 with cytokines. For comparison, EV-expressing cells were also treated with 2.5 \(\mu\)M imatinib. CC\textsuperscript{mut3} reduced cell growth by more than 2-fold as determined by trypan blue
exclusion, a significant reduction compared to inhibition by imatinib (Figure 4a). Cells were also assessed for colony formation by plating in methylcellulose supplemented with growth factors. The effects of CC\textsuperscript{mut3} on colony formation were similar to that of imatinib, inhibiting CML CD34\textsuperscript{+} cells from four independent newly diagnosed patient samples by ~60% (Figure 4b).

Additionally, we investigated the effect of CC\textsuperscript{mut3} expression on primary human CD34\textsuperscript{+} CML cells expressing BCR-ABL\textsubscript{1}T315I as determined by Sanger sequencing of two samples (R1 and R2) obtained from the same individual at two time points approximately 6 months apart, during which the patient was treated with ponatinib (Supplemental Table 1). Ponatinib was used to assess sensitivity to inhibition of BCR-ABL\textsubscript{1} catalytic activity. In the initial sample (R1) obtained when the patient was in accelerated phase CML, 10 nM ponatinib and CC\textsuperscript{mut3} reduced colony formation by 47% and 76%, respectively (Figure 5a). In contrast, while cells obtained at the time of blastic transformation (R2) were insensitive to treatment with ponatinib, CC\textsuperscript{mut3} was still able to reduce colony formation by 25% (Figure 5b). Importantly, Sanger sequencing confirmed that the mutation status had not changed compared to the initial sample. Altogether, these data suggest that like ponatinib\textsuperscript{16, 18}, CC\textsuperscript{mut3} has activity in CML patients harboring the T315I mutant.

Discussion

TKIs are an effective and generally well-tolerated therapy for CML\textsuperscript{38}. However, a subset of patients fail TKIs due to drug resistance or intolerance\textsuperscript{14, 39–42}. BCR-ABL\textsubscript{1} kinase-dependent resistance is often the product of BCR-ABL\textsubscript{1} kinase domain mutations that impair or prevent TKI binding to the catalytic site\textsuperscript{12, 43, 44}, which has led to the development of second and third generation inhibitors. Because kinase domain-targeted inhibitors are subject to resistance arising from mutations in this domain, we examined the ability of CC\textsuperscript{mut3}, a coiled-coil dimerization domain inhibitor\textsuperscript{26}, to impair growth and viability of CML cells by disrupting oligomerization, the key event necessary for autophosphorylation and activation of BCR-ABL\textsubscript{1} kinase (Figure 6)\textsuperscript{22, 45}. CC\textsuperscript{mut3} was computationally designed to include mutations that not only enhance interactions with BCR-ABL\textsubscript{1}, but also to incorporate charge-charge repulsions that destabilize CC\textsuperscript{mut3} homodimer formation. The net result is the preferential heterodimerization between CC\textsuperscript{mut3} and BCR-ABL\textsubscript{1}\textsuperscript{25, 26}.

Previous studies demonstrated that CC\textsuperscript{mut3} inhibits proliferation and induces apoptosis in K562 CML cells\textsuperscript{26}. Here, we report the effects of CC\textsuperscript{mut3} against native and mutant BCR-ABL\textsubscript{1}, using murine pro-B cells (Ba/F3) engineered to express native and kinase domain mutant BCR-ABL\textsubscript{1}, as well as primary CML CD34\textsuperscript{+} cells obtained from newly diagnosed or therapy-resistant patients. We found that CC\textsuperscript{mut3} reduced proliferation and colony formation and increased apoptosis of CML cell lines and patient samples expressing native BCR-ABL\textsubscript{1} (Figures 1b, 1d, 1f, and 4); CC\textsuperscript{mut3} had no measurable toxicity in BCR-ABL\textsubscript{1}-negative cells (Figures 1a, c, e). Importantly, this is the first evidence of CC\textsuperscript{mut3} efficacy in primary CML patient samples.

While all TKIs currently act directly on the kinase domain, we demonstrate that alternative mechanisms of BCR-ABL\textsubscript{1} inhibition can circumvent mutation-driven TKI resistance.
Consistent with native BCR-ABL1 inhibition by CCmut3, the CC mimic is effective in single BCR-ABL1 kinase domain mutants. We found a significant inhibition of growth and viability introduced by CCmut3 in BCR-ABL1E255V and BCR-ABL1T315I (Figures 2a and 2b), as well as a >5-fold increase in apoptosis (Figures 2c and 2d). Moreover, we observed a marked reduction of colony forming potential in both Ba/F3 cells expressing BCR-ABL1E255V and BCR-ABL1T315I (Figures 2e and 2f) and in a sample from a BCR-ABL1T315I CML patient following CCmut3 expression (Figure 5a). However, CCmut3 showed only minimal activity in a longitudinal sample obtained after the patient had developed resistance to ponatinib and progressed to the blastic phase of disease (Figure 5b). These data suggest that this patient may have developed a BCR-ABL1 kinase-independent mechanism of resistance.

The emergence of compound mutations in the kinase domain that confer resistance to multiple TKIs is of increasing clinical importance. To this end, we examined CCmut3 in compound-mutant BCR-ABL1E255VT315I cells, which are resistant to ponatinib, the most advanced tyrosine kinase inhibitor in clinical use. Importantly, CCmut3 significantly increased apoptosis and reduced colony formation of BCR-ABL1E255VT315I-expressing cells (Figure 3b, 3c), with a lesser effect on cell proliferation (Figure 3a). The cause of the comparably weaker activity of CCmut3 in cell proliferation assays is unknown and remains to be determined in structural studies. Taken together, we show that CCmut3 expression is not only effective against CML cells expressing native and single kinase domain mutant BCR-ABL1, but also against cells harboring compound-mutant BCR-ABL1 that are resistant to multiple TKIs, providing proof of principle that targeting the dimerization domain of BCR-ABL1 can overcome kinase domain mutation-based TKI resistance (Figure 6). Furthermore, we speculate that CCmut3 will not be prone to mutational escape routes seen with traditional kinase inhibitors (the selection or genesis of mutant BCR-ABL1 molecules which are TKI-resistant), because any mutations in BCR-ABL1 that would reduce binding to the CCmut3 would also reduce the ability of BCR-ABL1 to dimerize, thereby precluding autophosphorylation and resulting in a monomeric, auto-inhibited kinase. This may translate into a lower likelihood of clinical resistance due to point mutations. Another as yet hypothetical advantage of blocking dimerization may be the inhibition of BCR-ABL1 functions that are kinase-independent, yet require formation of BCR-ABL1 dimers or multimers. These functions persist upon TKI-mediated inhibition of BCR-ABL1 and may contribute to the innate TKI resistance of primitive CML cells.

In contrast to small molecule drugs, peptides present considerably greater drug delivery challenges. In the present study, CCmut3 was transcribed in cells following lentiviral infection with an expression construct. Direct application of this therapy could include intramedullary injection of lentivirus encoding CCmut3 as explored in hemophilia therapy. However, a challenge with this approach in cancer is to achieve 100% transduction efficiency. Therefore, we are currently formulating CCmut3 as a stapled peptide for therapeutic use in future in vivo studies. Stapled peptides improve drug delivery by their resistance to degradation, improved cell permeation, and increased in vivo half-life compared to conventional peptide therapeutics. Addition of a leukemia-specific cell-penetrating peptide motif might allow targeting of this peptide to CML stem cells.
instance, recent reports have identified antigens specifically or preferentially expressed on primitive CML cells, such as CD25, CD26 and the interleukin-1 receptor associated protein (IL1RAP)\textsuperscript{52,53}. Therefore, an antibody-C\textsuperscript{mut3} peptide conjugate could be formulated for leukemic stem cell targeting. Combination of BCR-ABL inhibition by CC\textsuperscript{mut3} along with inhibition of stem cell survival or self-renewal pathways may result in robust eradication of the CML stem cell\textsuperscript{54}.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

The authors are supported by the National Institutes of Health (grants HL082978-01, CA04963920A2 and 1R01CA178397 to MWD and grant CA129528 to CSL) and by the Leukemia & Lymphoma Society (grant 7036-01 to MWD). MWD was supported in part by a clinical research scholarship of the Leukemia & Lymphoma Society. DWW was supported in part by a grant to The University of Utah from the Howard Hughes Medical Institute through the Med into Grad Initiative, and by the Graduate Research Fellowship from The University of Utah. AME is currently a scholar of the American Society of Hematology. The authors acknowledge the use of DNA/Peptide Core and Flow Cytometry Core (NCI Cancer Center Support Grant P30 CA042014, Huntsman Cancer Institute). We acknowledge support of funds in conjunction with grant P30 CA042014 awarded to the Huntsman Cancer Institute. We would also like to thank Karina Matissek and Abood Okal for technical assistance and useful scientific discussions.

**References**

1. Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut. 1962 Apr;8:65–66. [PubMed: 14480647]
2. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983 Nov 17–23; 306(5940):277–280. [PubMed: 6580527]
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996 May; 2(5):561–566. [PubMed: 8616716]
4. Naldini L, Stacchini A, Cirillo DM, Aglietta M, Gavosto F, Comoglio PM. Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells. Molecular and cellular biology. 1986 May; 6(5):1803–1811. [PubMed: 2431286]
5. Evans JP, Wickremasinghe RG, Hoffbrand AV. Tyrosine protein kinase substrates in Philadelphia-positive human chronic granulocytic leukemia derived cell lines (K562 and BV173): detection by using an immunoblotting technique. Leukemia. 1987 Jun; 1(6):524–525. [PubMed: 2444834]
6. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012 Sep; 26(9):2096–2102. [PubMed: 22446502]
7. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530–3539. [PubMed: 11986204]
8. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15; 109(6):2303–2309. [PubMed: 17138817]
9. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with
imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834–1839. [PubMed: 18048643]

10. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993 Jul 15; 82(2):398–407. [PubMed: 8329700]

11. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995 Aug 1; 86(3):906–916. [PubMed: 7620184]

12. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003 Jul 1; 102(1):276–283. [PubMed: 12623848]

13. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003 Mar 21; 112(6):831–843. [PubMed: 12654249]

14. Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 2011 Nov-Dec;17(6):477–486. [PubMed: 22157291]

15. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature reviews Cancer. 2007 May; 7(5):345–356. [PubMed: 17457302]

16. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England journal of medicine. 2012 Nov 29; 367(22):2075–2088. [PubMed: 23190221]

17. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England journal of medicine. 2013 Nov 7; 369(19):1783–1796. [PubMed: 24180494]

18. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell. 2014 Sep 8; 26(3):428–442. [PubMed: 25132497]

19. O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6; 16(5):401–412. [PubMed: 19878872]

20. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature reviews Cancer. 2009 Jan; 9(1):28–39. [PubMed: 19104514]

21. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002 Feb; 9(2):117–120. [PubMed: 11780146]

22. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Molecular and cellular biology. 1993 Dec; 13(12):7587–7595. [PubMed: 8246975]

23. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, et al. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. International journal of cancer Journal international du cancer. 2008 Jun 15; 122(12):2744–2752. [PubMed: 18366061]

24. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia. 2009 Dec; 23(12):2242–2247. [PubMed: 19798092]

25. Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimp AA, Cheatham TE 3rd, et al. Disruption of Bcr-Abl coiled coil oligomerization by design. The Journal of biological chemistry. 2011 Aug 5; 286(31):27751–27760. [PubMed: 21659527]

26. Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, et al. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis. Molecular pharmaceutics. 2012 Jan 1; 9(1):187–195. [PubMed: 22136227]
27. Miller GD, Woessner DW, Sirch MJ, Lim CS. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML. Molecular pharmaceutics. 2013 Sep 3; 10(9):3475–3483. [PubMed: 23915432]
28. Daley GQ, Van Etten RA, Baltimore D. Blast crisis in a murine model of chronic myelogenous leukemia. Proceedings of the National Academy of Sciences of the United States of America. 1991 Dec 15; 88(24):11335–11338. [PubMed: 1763047]
29. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer research. 2002 Dec 15; 62(24):7149–7153. [PubMed: 12499247]
30. O’Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 2004 Oct 15; 104(8):2532–2539. [PubMed: 15256422]
31. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D. Growth of factor-dependent hemopoietic precursor cell lines. The Journal of experimental medicine. 1980 Oct 1; 152(4):1036–1047. [PubMed: 6968334]
32. Corbin AS, O’Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, et al. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013 Sep 15; 73(18):5775–5786. [PubMed: 23887971]
33. Fleischman AG, Aichberger KJ, Luty SB, Bummm TG, Petersen CL, Doratotaj S, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011 Dec 8; 118(24):6392–6398. [PubMed: 21860020]
34. Eide CA, Zabriskie MS, Adrian LT, Lange T, Deininger MW, Druker BJ, et al. Resistance Profiling of BCR-ABL Compound Mutations Linked to Tyrosine Kinase Inhibitor Therapy Failure in Chronic Myeloid Leukemia. Blood. 2011 Nov 18; 118(21):616–616. [PubMed: 19075254]
35. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009 Jan 20; 27(3):469–471. [PubMed: 19075254]
36. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013 Jan 17; 121(3):489–498. [PubMed: 23223358]
37. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. The Journal of clinical investigation. 2007 Sep; 117(9):2562–2569. [PubMed: 17710227]
38. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. American journal of hematology. 2012 Nov; 87(11):1037–1045. [PubMed: 23090888]
39. Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, et al. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010 Oct 1; 116(19):4564–4572. [PubMed: 20572041]
40. Jabbour E, Hochhaus A, Cortes J, La Rosee P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6–12. [PubMed: 19798095]
41. Hehlmann R, Lauseker M, Jung-Munkwitz M, Le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, et al. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010 Oct 1; 116(19):4564–4572. [PubMed: 20572041]
42. O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007 Oct 1; 110(7):2242–2249. [PubMed: 17496200]
43. Carella AM, Garuti A, Cirmena G, Catania G, Rocco I, Palermo C, et al. Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Leukemia & lymphoma. 2010 Feb; 51(2):275–278. [PubMed: 20038234]

44. Klamova H, Faber E, Zackova D, Markova M, Voglova J, Cmunt E, et al. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematologic centers in the Czech Republic. Neoplasma. 2010; 57(4):355–359. [PubMed: 20429627]

45. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Molecular cell. 2003 Jul; 12(1):27–37. [PubMed: 12887890]

46. Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2014 Aug 19.

47. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug discovery today. 2003 Mar 15; 8(6):259–266. [PubMed: 12623240]

48. Wang X, Chen L, Ye P, Chiang A, Miao CH. Development of Direct Intra-Bone Marrow Gene Transfer of Lentiviral Vectors Containing a B-Domain Variant of Human Factor VIII for Hemophilia A Treatment. ASH Annual Meeting Abstracts 2011. Nov 18.2011 118(21):4710.

49. Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. Journal of medicinal chemistry. 2014 Aug 14; 57(15):6275–6288. [PubMed: 24601557]

50. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Therapeutic delivery. 2013 Nov; 4(11):1443–1467. [PubMed: 24228993]

51. Nishimura S, Takahashi S, Kamikatahira H, Kuroki Y, Jaalouk DE, O’Brien S, et al. Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells. The Journal of biological chemistry. 2008 Apr 25; 283(17):11752–11762. [PubMed: 18292083]

52. Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proceedings of the National Academy of Sciences of the United States of America. 2010 Sep 14; 107(37):16280–16285. [PubMed: 20805474]

53. Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014 Jun 19; 123(25):3951–3962. [PubMed: 24778155]

54. Jamieson CH. Chronic myeloid leukemia stem cells. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2008:436–442. [PubMed: 19074122]
Figure 1. **CCmut3** reduces proliferation, increases apoptosis, and impairs survival of Ba/F3 cells expressing native BCR-ABL1, with no effect on parental Ba/F3 cells

(a, b) Proliferation of Ba/F3 parental cells were not affected by expression of the **CCmut3** (blue boxes) compared to EV controls (red circles) (a), whereas **CCmut3** treatment of Ba/F3 cells expressing native BCR-ABL1 significantly reduced proliferation at 96 h compared to controls (b). (c, d) Apoptotic cell populations at 72 h were quantified following flow cytometric analyses of transfected (GFP+) cells. Panels indicate apoptotic populations (Annexin V-positive/7-AAD-negative) of Ba/F3 parental cells (c), and Ba/F3 cells expressing native BCR-ABL1 (d). (e, f) Colony forming ability of Ba/F3 parental cells were not affected by expression of the EV control or **CCmut3** (e), while colony formation by Ba/F3 cells expressing native BCR-ABL1 was greatly reduced in the **CCmut3** treatment group compared with EV (f) (n=3). All graphs display mean ± S.E.M. **p<0.01, ***p<0.001.
Figure 2. CC\textsuperscript{mut3} inhibits BCR-ABL1-driven proliferation and increases apoptosis in single-mutant BCR-ABL1

(a, b) A significant reduction of proliferative capacity was observed following CC\textsuperscript{mut3} (blue boxes) but not EV expression (red circles) of Ba/F3 cells expressing the single BCR-ABL1 mutants E255V (a) or T315I (b) at both 72 and 96 h (n=3). (c, d) An increase of apoptosis was observed in Ba/F3 BCR-ABL1\textsuperscript{E255V} (c) and Ba/F3 BCR-ABL1\textsuperscript{T315I} (d) cells at 72 h. (e, f) Colony formation of Ba/F3 mutants E255V (e) and T315I (f) represented significantly fewer colonies per unit area CC\textsuperscript{mut3} compared to EV groups (n=3). Graphs display mean ± S.E.M. **p<0.01, ***p<0.001.
Figure 3. CCmut3 enhances apoptosis, and reduces colony forming ability of compound-mutant BCR-ABL1 cells 

(a) Ba/F3 cells expressing the BCR-ABL1\textsuperscript{E255V/T315I} compound mutant demonstrate a small yet significant growth reduction at 96 h but not 72 h with CC\textsuperscript{mut3} treatment compared to EV controls (n=3). (b) Enhanced apoptosis was evident in Ba/F3 BCR-ABL1\textsuperscript{E255V/T315I} cells when expressing CC\textsuperscript{mut3} compared to EV controls (n=3). (c) Colonies per unit area were again reduced in the compound mutant cell line (Ba/F3 BCR-ABL1\textsuperscript{E255V/T315I}) by CC\textsuperscript{mut3} compared to EV controls (n=3). Graphs display mean ± S.E.M. *p<0.05, **p<0.01.
Figure 4. Cells from newly diagnosed CML patients are sensitive to $C^{mut3}$ lentiviral therapy \textit{ex vivo}.

(a) Equal number of cells were seeded on day 0 for each group and plotted as fold-change of starting cell number compared to controls on days 2–7. Imatinib was added on days 0 and 4 (indicated by orange arrows) to the EV+2.5 μM imatinib group only ($n=3$). *$p<0.05$ compared to EV, ***$p<0.001$ compared to EV, _$p<0.05$ compared to EV+2.5 μM imatinib group. (b) Colony forming cells were assessed 14 days following seeding in methylcellulose. Individual patient samples were counted in duplicate and normalized to the EV control. 2.5 μM imatinib and $C^{mut3}$ are equally effective in reducing colony number ($n=4$). Graphs display mean ± S.E.M. ***$p<0.001$. 

\textit{Leukemia}. Author manuscript; available in PMC 2016 February 01.
Figure 5. $CC^{mut3}$ is effective in a patient sample from a CML patient in accelerated phase harboring BCR-ABL1$^{T315I}$, with a less pronounced effect upon blastic transformation

Colony forming assays were set up with two longitudinal samples from the same patient, R1 and R2, separated by a 6-month interval. Each sample was thawed and lentivirally transduced with $CC^{mut3}$ or the EV control. Following cell sorting for transduction, each sample was plated in triplicate. (a) R1 displays sensitivity to 10 nM ponatinib (gray checked bars), but even greater sensitivity to transduction with $CC^{mut3}$ (blue checked bars) compared to untreated EV-transduced controls (red solid bar). (b) R2 is a sample from the same individual after ponatinib failure and transformation to blast crisis (see Supplemental Table 1). While ponatinib treatment minimally increases colony forming ability, $CC^{mut3}$ treatment resulted in a ~25% reduction in colony formation.
Figure 6. BCR-ABL1 inhibition state in native and mutant forms by TKI or by CC\textsuperscript{mut3}

(a) TKIs bind to the catalytic site of the BCR-ABL1 fusion protein. Proliferation and survival are blocked through kinase inhibition, irrespective of dimerization. (b) In compound mutant BCR-ABL\textsubscript{E255V/T315I}, TKIs are unable to bind to the catalytic site. Dimerization and kinase activity remain intact. (c) CC\textsuperscript{mut3} expression leads to competitive disruption of dimerization, preventing transphosphorylation, autophosphorylation and kinase activation of native, single and compound mutant BCR-ABL1.